Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in COVID-19
NCT04394442Phase 2Unknown
- Start
- Mar 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoints: Time to viral clearance at 21 days and Percentage of mortality at 60 days. Status: unknown.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04394442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04394442.